Publication
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.
Authors not recorded
Oncotarget2016PMID 26683709PMC4826228stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- cancerMalignant Neoplasmcivic_curation1.00
- geneEZH2civic_curation1.00
- variantEZH2 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26683709
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EZH2 Overexpression1 | ||||||||
| (prognostic) | Malignant NeoplasmALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID731High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients. PMID 26683709 · Jiang et al., 2016 · Open in CIViC | civic |